Forensic Analysis · Professional & Commercial Services · as of Aug 12, 2026
Claritev Corp (CTEV)
A forensic read on Claritev Corp built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Distress
Financial health
-1.5
Distress distance
Clean
Earnings quality
5
Forensic signals
-1.9
P / E (ttm)
$592M
Market cap
0.00%
Dividend yield
3.7%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Claritev Corp earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads -1.5, placing it in the Distress zone. 5 forensic signals were flagged in its latest SEC filings, led by receivables vs revenue.
What the filings flag
41d DSO
FY2024→FY2025
Receivables vs revenue.Days sales outstanding moved from 33 to 41 days FY2024→FY2025 (receivables +42% vs revenue +4%). Receivables are outrunning sales — a flag for aggressive revenue recognition or slipping collections. Across FY2021–FY2025 the day count ran 27 → 30 → 30 → 33 → 41 days — the latest step continues a climb that was already under way, which is the persistence that separates a collection problem from a busy quarter.
0.5%
FY2025
Return on invested capital.Return on invested capital is 0.5% in the latest fiscal year and rising from -4% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
stopped
FY2024→FY2025
Shareholder returns — halted.Capital returns have STOPPED — $10M of buybacks + dividends in FY2024, but ~$0 in FY2025. A halt usually means the company is conserving cash.
n/m (stock split)
FY2022–FY2025
Share count (stock split).Diluted share count changed -97% over the last 3 years to FY2025, but that includes a large one-time change around FY2023 consistent with a stock split or reverse split, not gradual buybacks or issuance — a split changes the count with NO effect on any holder's proportional ownership, so the raw -70.5%/yr figure isn't a real buyback/dilution read here.
$2.1B
FY2022–FY2024
Goodwill impairments.Took $2.1B of goodwill writedowns across 2 years (FY2022 ($658M), FY2024 ($1.4B)). Writedowns mean past acquisitions underperformed what was paid for them.
Key fundamentals
Latest Revenue$965.4M
Revenue Growth YoY+3.7%
Revenue CAGR (3yr)-3.7%
Net Margin-29.4%
Free Cash Flow-$12.3M
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Claritev Corp's actual 10-K/10-Q/8-K filings?